Literature DB >> 12168922

Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report.

Pietro Citarrella1, Vittorio Gebbia, Michele Teresi, Salvatore Miceli, Giovanna Sciortino, Marina Vaglica, Nicolina Pizzardi, Sergio Palmeri.   

Abstract

A case of hemolytic uremic syndrome is reported in a female patient affected by metastatic breast carcinoma receiving chemotherapy with gemcitabine and docetaxel. Up to now this is the first case that has been reported in the medical literature in patients treated with docetaxel (taxotere)and gemcitabine. The patient developed hemolytic uremic syndrome after the third cycle of chemotherapy. She was treated with diuretics, steroids, antibiotics, antifungal drugs, erythropoietin and fluid replacement. The patient underwest dialysis, and survived the hemolytic uremic syndrome. It was not possible to ascertain if the hemolytic uremic syndrome was related to the chemotheraputic treatment or the cancer itself.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168922

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer.

Authors:  Victor C Kok; Sheng-Chung Wu; Chien-Kuang Lee
Journal:  Breast Cancer (Auckl)       Date:  2014-03-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.